Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
Withdrawn
Sidney Kimmel Cancer Center at Thomas Jefferson University
2003-02-01
Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use,
the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and
elimination) of this therapy. The researchers are also interested in evaluating the
pharmacokinetics of the various immunosuppressant medications that patients will receive such
as tacrolimus, mycophenolate mofetil and daclizumab.
The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease
Completed
University of Wisconsin, Madison
N/A
2000-01-01
This pilot study is to assess whether using CytoGam® in combination with ganciclovir is more
effective in reducing the CMV viral load over time, as compared to standard treatment with IV
ganciclovir only. Serial blood samples are drawn to measure the amount of CMV viral load
weekly, while the subject is receiving treatment with ganciclovir, or ganciclovir + CytoGam®.
Additional CMV viral load blood sampling (CMV DNA capture qualitative testing only) will
occur weekly thereafter until the subject is 8 weeks from the time of CMV diagnosis or until
the CMV infection is no longer detectable, whichever is longer duration.
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Completed
Johns Hopkins University
Phase 3
2007-01-01
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is
a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney
transplant recipients who have a positive crossmatch with their live donor.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
